High rate of hepatitis due to treatment with pyrazinamide (PYR) and ethambutol (EMB) for latent tuberculosis infection (LTBI) in subjects exposed to MDR-TB Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities Year: 2005
Tuberculosis (TB) relapse rate among patients treated with moxifloxacin (m) or ethambutol (E) in the intensive phase of therapy Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Treatment outcomes of tuberculosis (TB) patients with rifampin (RMP) or RMP and isoniazid (INH) resistance receiving standard regimen Source: Eur Respir J 2003; 22: Suppl. 45, 42s Year: 2003
The treatment of tuberculosis and application of HAART (highly active anti retroviral treatment) in HIV positive patients Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005
High completion rates with directly observed preventive treatment (DOPT) of latent tuberculosis infection (LTBI) in Ethiopian immigrants (EI) to Israel Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I Year: 2012
Timing of concurrent highly active antiretroviral therapy (HAART) in adults with tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 302s Year: 2006
Multi drug resistant (rifampicin + isoniazid) pulmonary tuberculosis – a challenge for a developing country specially co-infected with HIV Source: Eur Respir J 2007; 30: Suppl. 51, 421s Year: 2007
Treatment of multidrug-resistant tuberculosis (MDR-TB) with modified shorter all-oral treatment regimen (mSTR) under operational research conditions in Belarus Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Prevalence and treatment outcome of drug resistant pulmonary tuberculosis in HIV negative cases – experience from a tuberculosis treatment center in India Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis Year: 2009
Tolerance to rifampicine (RIF) 4 months vs. isoniazid (INH) 6 months for latent tuberculosis infection (LTBI) Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis Year: 2008
Treatment outcomes of tuberculosis patients under directly observed therapy (DOT) for three years Source: Eur Respir J 2004; 24: Suppl. 48, 653s Year: 2004
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Primary resistance (PR) of mycobacterium tuberculosis (MBT) to antimicrobial drugs (AMBD) in patients (P) with destructive pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 655s Year: 2004
The use of phon resonant therapy (PRT) in treatment of patients with pulmonary tuberculosis, combined with infections, caused by chlamydia (C) and mycoplasma (M) Source: Eur Respir J 2004; 24: Suppl. 48, 52s Year: 2004
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001
Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007
Tuberculin skin test (TST) conversions rates, its relationship with interferon gamma release assay and safety and efficacy of 4 months rifampicin therapy (4R) for latent TB infection (LTBI) among nursing students in south India Source: Annual Congress 2010 - Special treatment options in tuberculosis Year: 2010
When do we extend the treatment of tuberculosis (TB) more than 6 months? Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007
One year follow-up of T-SPOT. TB results in treated patients with active tuberculosis Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease Year: 2007
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015